Economic evaluations of hepatitis B vaccination for developing countries

References

• Aggarwal R, Ghoshal UC, Naik SR. Assessment of cost–effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model. J. Hepatol.38(2), 215–222 (2003).
   PubMed Web of Science ®Google Scholar
• Vimolket T, Poovorawan Y. An economic evaluation of universal infant vaccination strategies against hepatitis B in Thailand: an analytic decision approach to cost–effectiveness. Southeast Asian J. Trop. Med. Public Health36(3), 693–699 (2005).
   PubMedGoogle Scholar
• Liu ZG, Zhao SL, Zhang YX. Cost–benefit analysis on immunization of newborns with hepatitis B vaccine in Jinan City. Chin. J. Epidemiol.16, 81–84 (1995).
   Google Scholar
• Hu R, Cao W, Zhang X: Cost–effectiveness analysis of hepatitis B vaccination in People’s Liberation Army. Zhonghua Liu Xing Bing Xue Za Zhi22(2), 142–145 (2001).
   PubMedGoogle Scholar
• WHO. Western Pacific Regional Plan For Hepatitis B Control Through Immunization. WHO, Geneva, Switzerland (2007).
   Google Scholar
• Sahni M, Jindal K, Abraham N, Aruldas K, Puliyel JM. Hepatitis B immunization: cost calculation in a community-based study in India. Indian J. Gastroenterol.23(1), 16–18 (2004).
   PubMedGoogle Scholar
• Prakash C. Crucial factors that influence cost–effectiveness of universal hepatitis B immunization in India. Int. J. Technol. Assess. Health Care19(1), 28–40 (2003).
   PubMed Web of Science ®Google Scholar
• Kim SY, Salomon JA, Goldie SJ. Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness affordability curves. Bull. World Health Organ.85(11), 833–842 (2007).
   PubMed Web of Science ®Google Scholar
• Griffiths UK, Hutton G, Das Dores PE. The cost–effectiveness of introducing hepatitis B vaccine into infant immunization services in Mozambique. Health Policy Plan20(1), 50–59 (2005).
   PubMed Web of Science ®Google Scholar
• Edmunds W, Dejene A, Mekonnen Y, Haile M, Alemnu W, Nokes D. The cost of integrating hepatitis B virus vaccine into national immunization programmes: a case study from Addis Ababa. Health Policy Plan15(4), 408–416 (2000).
   PubMed Web of Science ®Google Scholar
• Hall AJ, Roberston RL, Crivelli PE et al. Cost–effectiveness of hepatitis B vaccine in the Gambia. Trans. R. Soc. Trop. Med. Hyg.87(3), 333–336 (1993).
   PubMed Web of Science ®Google Scholar
• Adibi P, Rezailashkajani M, Roshandel D et al. An economic analysis of premarriage prevention of hepatitis B transmission in Iran. BMC Infect. Dis.4, 31 (2004).
   PubMedGoogle Scholar
• WHO. Regional Strategic Plan for the Expanded Programme on Immunization, 2006–2009. WHO, Geneva, Switzerland (2006).
   Google Scholar
• Mulley AG, Silverstein MD, Dienstag JL. Indications for use of hepatitis B vaccine, based on cost–effectiveness analysis. N. Engl. J. Med.126, 716–721 (1982).
   Google Scholar
• Van Damme P, Vorsters A. Hepatitis B control in Europe by universal vaccination programmes: the situation in 2001. J. Med. Virol.67(3), 433–439 (2002).
   PubMed Web of Science ®Google Scholar
• Prakash C, Sharma RS, Bhatia R, Verghese T, Datta KK. Prevalence of North India of hepatitis B carrier state amongst pregnant women. Southeast Asian J. Trop. Med. Public Health29(1), 80–84 (1998).
   PubMedGoogle Scholar
• Van Damme P, Kane M, Andre M. Integration of hepatitis B vaccination into national immunization programmes. Br. Med. J.314(7086) 1033–1037 (1997).
   PubMed Web of Science ®Google Scholar
• Hudeckova H, Straka S, Szilagyiova M, Avdicova M, Rusnakova S: Cost effectiveness and cost benefit of viral hepatitis B vaccination in the Slovak Republic. Cent. Eur. J. Public Health10(4), 146–148 (2002).
   PubMedGoogle Scholar
• Adam T, Baltussen R, Tan Torres T et al. Making choices in health: WHO guide to cost–effectiveness analysis. WHO, Geneva, Switzerland (2003).
   Google Scholar
• Beutels P. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994–2000). Health Econ.10(8), 751–774 (2001).
   PubMed Web of Science ®Google Scholar
• Kim SY, Goldie SJ. Cost–effectiveness analyses of vaccination programmes. Pharmacoeconomics26(3), 191–215 (2008).
   PubMed Web of Science ®Google Scholar
• World Bank. Investing in health. Washington, DC, World Bank (1993).
   Google Scholar
• WHO. Core Information for the Development of Immunization Policy: 2002 Update. WHO, Geneva, Switzerland (2002).
   Google Scholar
• Kretzschmar M, Mangen MJ, van de Laar M, de Wit A. Model based analysis of hepatitis B vaccination strategies in The Netherlands. Vaccine27(8), 1254–1260 (2009).
   PubMed Web of Science ®Google Scholar
• Gravelle H, Smith D. Discounting for health effects in cost–benefit and cost effectiveness analysis. Health Econ.10, 581–594 (2001).
   Web of Science ®Google Scholar
• Parsonage M, Neuburger H. Discounting and health benefits. Health Econ.1, 71–76 (1992).
   PubMedGoogle Scholar
• Cooper N, Coyle D, Abrams K, Mugford M, Sutton A. Use of evidence in decision models: an appraisal of health technology assessments in the UK since 1997. J. Health Serv. Res. Policy10(4), 245–250 (2005).
   PubMedGoogle Scholar
• FitzSimons D, Van Damme P. Prevention and control of hepatitis B in central and eastern Europe and the newly independent states, Siofok, Hungary, 6–9 October 1996. Vaccine15, 1595–1597 (1997).
   PubMed Web of Science ®Google Scholar
• Van Damme P, Vellinga A. Epidemiology of hepatitis B and C in Europe. Acta Gastro-Enterol. Belg.61, 175–182 (1998).
   PubMed Web of Science ®Google Scholar
• Holliday SM, Faulds D. Hepatitis B vaccine: a pharmacoeconomic evaluation of its use in the prevention of hepatitis B virus infection. Pharmacoeconomics5(2), 141–171 (1994).
   PubMed Web of Science ®Google Scholar